Organization
CFCE - Dana-Farber Cancer Institute
1 abstract
Abstract
Characterizing genomic alterations in patients with metastatic urothelial carcinoma (mUC) treated with enfortumab-vedotin (EV) with a focus on 1q23.3.Org: CFCE - Dana-Farber Cancer Institute, Mass General Brigham,